《大行》匯豐研究降創科實業(00669.HK)目標價至112元 維持評級「買入」
匯豐研究發表研究報告指,創科實業(00669.HK)上半年收入按年升7.1%,符合預期,毛利率升34個基點至40.3%,符合預期。受惠行政支出的嚴格控制,營運利潤率升49個基點至9.1%,勝於預期。
該行指,將集團2025年至2027年收入預測下調0.4%至0.5%,並將2025年至2027年息稅前利潤率預測下調0.1至0.5個百分點,而各年每股盈餘預測分別下調2.9%、6.9%及2.9%,其目標價由120元下調至112元,維持其評級為「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.